Kancera AB | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
7,404.00
16,095.00
19,686.00
22,282.00
56,143.00
Depreciation, Depletion & Amortization
709.00
1,024.00
1,088.00
1,117.00
1,168.00
Other Funds
-
4,686.00
-
5,743.00
-
Funds from Operations
9,709.00
14,955.00
17,893.00
20,900.00
55,149.00
Changes in Working Capital
3,071.00
4,150.00
2,765.00
2,203.00
1,608.00
Net Operating Cash Flow
6,638.00
19,105.00
20,658.00
23,103.00
53,541.00
Capital Expenditures
2,000.00
601.00
366.00
-
-
Sale of Fixed Assets & Businesses
-
-
-
-
364.00
Net Investing Cash Flow
2,000.00
601.00
366.00
-
364.00
Issuance/Reduction of Debt, Net
1,500.00
-
-
-
-
Net Financing Cash Flow
17,649.00
28,562.00
13,617.00
65,295.00
23,193.00
Net Change in Cash
9,011.00
8,856.00
7,407.00
42,192.00
29,984.00
Free Cash Flow
8,638.00
19,706.00
21,024.00
23,103.00
53,541.00
Change in Capital Stock
16,149.00
23,876.00
13,617.00
59,552.00
23,193.00

About Kancera AB

View Profile
Address
Karolinska Institutet Science Park
Solna AB 171 48
Sweden
Employees -
Website http://www.kancera.com
Updated 09/14/2018
Kancera AB engages in the research, development, and sale of drug candidate to pharmaceutical companies. Its portfolio includes Fractalkine, ROR inhibitors, HDAC6, and PFKFB3 projects. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.